Excitotoxicity and dopaminergic dysfunction in the acquired immunodeficiency syndrome dementia complex. Therapeutic implications.
Human immunodeficiency virus infection is frequently complicated by a syndrome of central nervous system dysfunction known as the acquired immunodeficiency syndrome dementia complex (ADC). The ADC is characterized by abnormalities in cognition, motor performance, and behavior, and it produces serious morbidity in a significant number of patients with acquired immunodeficiency syndrome. The pathogenesis of ADC is unclear, but appears to be caused by the human immunodeficiency virus itself, rather than by a secondary opportunistic process. Herein, we review the data regarding the pathogenesis of ADC and hypothesize a mechanism involving excitotoxicity and dopaminergic dysfunction. N-methyl-D-aspartate receptor antagonists may be of therapeutic benefit, as these agents may both limit glutamate-mediated neuronal dysfunction and improve dopaminergic neuronal function.
Kieburtz
K D
KD
Department of Neurology, University of Rochester Medical Center, NY 14642.
Epstein
L G
LG
Gelbard
H A
HA
Greenamyre
J T
JT
D015526:AIDS Dementia Complex / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism* / Q000473:pathology; D000328:Adult; D001921:Brain / Q000378:metabolism; D017321:Clinical Trials, Phase I as Topic; D004298:Dopamine / Q000378:metabolism*; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D009474:Neurons / Q000378:metabolism; D010300:Parkinson Disease / Q000188:drug therapy; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors / Q000378:metabolism*; D015215:Zidovudine / Q000627:therapeutic use
D016194:Receptors, N-Methyl-D-Aspartate; D007980:Levodopa; D015215:Zidovudine; D004298:Dopamine